1
|
Russcher A, van Boven M, Benincà E, Verweij EJTJ, Molenaar-de Backer MWA, Zaaijer HL, Vossen ACTM, Kroes ACM. Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic. Sci Rep 2024; 14:9630. [PMID: 38671058 PMCID: PMC11053065 DOI: 10.1038/s41598-024-59582-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Accepted: 04/12/2024] [Indexed: 04/28/2024] Open
Abstract
Parvovirus B19V (B19V) infection during pregnancy can be complicated by potentially life-threatening fetal hydrops, which can be managed by intrauterine transfusion (IUT). This study investigates the long-term temporal patterns in the epidemiology of B19V and evaluates the impact on fetal hydrops, by combining data on B19V infections from the Dutch Sentinel Surveillance system in the period 1990 to 2023, Dutch blood banking data and hospital data on fetal hydrops. Using wavelet analysis, we identified annual epidemic cycles in the Netherlands in the period 1990-2019 and we identified superimposed multiannual cycles in the period 1990-2009. After 2009, no multiannual cycle could be identified, although the incidence fluctuated and correlates with number of IUT performed. As of 2020, weekly reports of B19V infection demonstrated a historically low incidence and B19V-DNA positive blood donors were nearly absent. From May 2020 to May 2023, no IUT for B19V-related hydrops was performed. In the spring of 2023, B19V infections re-emerged, reaching pre-pandemic epidemic levels. Due to the changes in B19V epidemiology over the last 30 years and the near-absence of B19V during the COVID-19 pandemic, the resulting low immunity levels may lead to rebound outbreaks. Alertness to severe complications such as fetal hydrops is warranted.
Collapse
Affiliation(s)
- Anne Russcher
- LUCID Medical Microbiology and Infection Control, Leiden University Medical Center, Leiden, The Netherlands.
| | - Michiel van Boven
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Julius Center for Health Sciences and Primary Care, Department of Epidemiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Elisa Benincà
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - E J T Joanne Verweij
- Department of Obstetrics, Division of Fetal Therapy, Leiden University Medical Center, Leiden, The Netherlands
| | - Marijke W A Molenaar-de Backer
- Department of Blood-Borne Infections, Donor Medicine Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
| | - Hans L Zaaijer
- Department of Blood-Borne Infections, Donor Medicine Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
| | - Ann C T M Vossen
- LUCID Medical Microbiology and Infection Control, Leiden University Medical Center, Leiden, The Netherlands
| | - Aloys C M Kroes
- LUCID Medical Microbiology and Infection Control, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
2
|
Jiang H, Qiu Q, Zhou Y, Zhang Y, Xu W, Cui A, Li X. The epidemiological and genetic characteristics of human parvovirus B19 in patients with febrile rash illnesses in China. Sci Rep 2023; 13:15913. [PMID: 37741897 PMCID: PMC10517975 DOI: 10.1038/s41598-023-43158-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 09/20/2023] [Indexed: 09/25/2023] Open
Abstract
To understand the epidemiological and genetic characteristics of B19V, a multiple-province surveillance of patients with febrile rash illnesses (FRIs) were conducted in China during 2009 ~ 2021. The clinical specimens of 3,820 FRI patients were collected and tested for B19V DNA. A total of 99 (2.59%) patients were positive for B19V, and 49 (49.49%) were children under 5 years old. B19V infections occurred throughout the year without obvious seasonal pattern. Ten NS1-VP1u sequences and seven genome sequences were obtained in this study, identified as subgenotype 1a. Combined with the globally representative genome sequences, no temporal and geographic clustering trends of B19V were observed, and there was no significant correlation between B19V sequences and clinical manifestations. The evolutionary rate of the B19V genome was 2.30 × 10-4 substitutions/site/year. The number of negative selection sites was higher than that of positive selection sites. It was the first to comprehensively describe the prevalence patterns and evolutionary characteristics of B19V in FRI patients in China. B19V played the role in FRI patients. Children under 5 years old were the main population of B19V infection. Subgenotype 1a was prevalent in FRI patients in China. B19V showed a high mutation rate, while negative selection acted on the genome.
Collapse
Affiliation(s)
- Haoran Jiang
- National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China
- School of Public Health and Management, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, People's Republic of China
| | - Qi Qiu
- National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China
- Shanghai Municipal Center for Disease Control and Prevention, Institute of Infectious Disease Prevention and Control, 1380 Zhongshan West Road, Xuhui District, Shanghai, 200336, People's Republic of China
| | - Yangzi Zhou
- National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China
- NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People's Republic of China
| | - Yan Zhang
- National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China
| | - Wenbo Xu
- National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China
| | - Aili Cui
- National Health Commission (NHC) Key Laboratory of Medical Virology and Viral Diseases, WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
| | - Xiaomei Li
- School of Public Health and Management, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, People's Republic of China.
| |
Collapse
|
3
|
Sun P, Jiang P, Liu Q, Zhang R, Wang Z, Cao H, Ye X, Ji S, Han J, Lu K, He X, Fan J, Cao D, Zhang Y, Yin Y, Chen Y, Zhao X, Ye S, Su N, Du X, Ma L, Li C. Parvovirus B19 DNA and antibodies in Chinese plasma donors, plasma pools and plasma derivatives. PeerJ 2023; 11:e15698. [PMID: 37554334 PMCID: PMC10405795 DOI: 10.7717/peerj.15698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 06/14/2023] [Indexed: 08/10/2023] Open
Abstract
BACKGROUND Human parvovirus B19 (B19V) is a common contaminant found in plasma pools and plasma derivatives. Previous studies were mainly focused on limited aspects, further assessment of prevalence of B19V DNA and antibodies in plasma donors, the contamination of B19V in pooled plasma and plasma derivatives should be performed in China. STUDY DESIGN AND METHODS Individual plasma donors' samples from four provinces and pooled plasma from four Chinese blood product manufacturers were collected and screened using B19V DNA diagnostic kits between October 2018 and May 2020. The positive samples were investigated for the seroprevalence of B19V antibodies and subjected to sequence analysis and alignment for phylogenetic studies. Moreover, 11 plasma donors who were B19V DNA-positive at their first testing were also followed during the later donation period. Additionally, 400 plasma pools and 20 batches of plasma derivatives produced by pooled plasma with a viral load of B19V DNA exceeding 104IU/mL were also collected and tested for B19V DNA and antibodies. OBJECTIVES To comprehensively and systematically determine the frequency and viral load of B19V DNA in plasma donors, pooled plasma, and plasma derivatives from four Chinese blood product manufacturers. RESULTS A total of 17,187 plasma donors were analyzed and 44 (0.26%) specimens were found positive for B19V DNA. The quantitative DNA levels ranged from 1.01 × 101 to 5.09 × 1012 IU/mL. Forty-four DNA-positive specimens were also investigated for the seroprevalence of B19V antibodies, 75.0% and 2.3% of which were seropositive for B19V IgG and IgM antibodies, respectively. The phylogenic analyses showed that the prevalent genotypes in the four provinces' plasma donors belonged to B19V Genotype 1. Eleven individual plasma donors who were B19V DNA-positive at the first donation were then followed for a period, and in general, the DNA levels of B19V gradually decreased. Moreover, 64.8% (259/400) of the pooled plasma was contaminated by B19V, with concentrations of 1.05 × 100-3.36 × 109IU/mL. Approximately 72.6% of the DNA-positive plasma pools were only moderately contaminated (<104 IU/mL), while 27.4% contained >104 IU/mL. Twenty batches of plasma derivatives produced by pooled plasma with a viral load of B19V DNA exceeding 104IU/mL were also tested. B19V was detected in 5/5 PCC samples and 5/5 factor VIII samples but was not found in the intravenous immune globulin and albumin samples. CONCLUSION The contamination of B19V in pooled plasma and plasma-derived clotting factor concentrates is serious. Whether B19V nucleic acid testing (NAT) screening of plasma and plasma derivatives is launched in China, blood product manufacturers should spontaneously perform B19V NAT screening in plasma donors and mini-pool plasma. These measures can ensure that samples with high titer B19V DNA are discarded in order to prevent and control this transfusion transmitted virus.
Collapse
Affiliation(s)
- Pan Sun
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Peng Jiang
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Qing Liu
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Rong Zhang
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Zongkui Wang
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Haijun Cao
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | | | - Shangzhi Ji
- Beijing Wantai Biological Pharmacy, Beijing, China
| | - Jinle Han
- Beijing Wantai Biological Pharmacy, Beijing, China
| | - Kuilin Lu
- Chengdu Rongsheng Pharmaceutical Co., Ltd., Chengdu, China
| | - Xuexin He
- Chengdu Rongsheng Pharmaceutical Co., Ltd., Chengdu, China
| | - Jiajin Fan
- Shandong Taibang Biological Products Co., Ltd., Taian, China
| | - Dawei Cao
- Shandong Taibang Biological Products Co., Ltd., Taian, China
| | - Yu Zhang
- Hualan Biological Products Co., Ltd., Xinxiang, China
| | - Yongsheng Yin
- Hualan Biological Products Co., Ltd., Xinxiang, China
| | - Yunhua Chen
- Guizhou Taibang Biological Products Co., Ltd, Guiyang, China
| | - Xuemei Zhao
- Guizhou Taibang Biological Products Co., Ltd, Guiyang, China
| | - Shengliang Ye
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Na Su
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Xi Du
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Li Ma
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| | - Changqing Li
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
| |
Collapse
|
4
|
Taherkhani R, Farshadpour F, Norozi M. Molecular Evaluation of Human Parvovirus B19 Infection and Associated Risk Factors among Pregnant Women in Bushehr Province, Southern Iran. Am J Trop Med Hyg 2022; 106:tpmd211088. [PMID: 35483391 PMCID: PMC9128684 DOI: 10.4269/ajtmh.21-1088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 01/20/2022] [Indexed: 11/07/2022] Open
Abstract
Given the importance of human parvovirus B19 infection during pregnancy and the potential risks to the fetus, this study was designed to determine the prevalence, genotypic pattern, and risk factors of parvovirus B19 infection among a population-based sample of pregnant women in Bushehr Province, southern Iran. A total of 824 pregnant women were enrolled in this study. Serum samples were screened for the detection of anti-parvovirus B19 IgM and IgG by ELISA. The molecular evaluation was performed by nested polymerase chain reaction, targeting the non-structural protein 1-viral protein 1 unique region of the genome, and sequencing. Of 824 pregnant women, 330 (40.1%) were positive for anti-parvovirus B19 IgG and 50 women (6.1%) had anti-parvovirus B19 IgM. A greater rate of anti-parvovirus B19 IgG seroprevalence was observed in women older than 39 years, in Afghan immigrants, and in those women with more parities. Anti-parvovirus B19 IgM seroprevalence decreased with increasing gestational age and was significantly greater among women in the first trimester of pregnancy and among residents of the city of Borazjan. Moreover, 0.73% of the pregnant women had parvovirus B19 viremia with genotype 1 and subtype 1a. Parvovirus B19 DNA was detected in the samples collected in late autumn and winter, which is a rainy season associated with temperate climes in southern Iran. According to the results of this study, approximately 60% of pregnant women in this region are serologically negative and susceptible to parvovirus B19 infection. Therefore, assessment for maternal parvovirus B19 infection is important and should be considered as part of the fetal-maternal health policy in Iran.
Collapse
Affiliation(s)
- Reza Taherkhani
- Department of Virology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
| | - Fatemeh Farshadpour
- Department of Virology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
| | - Masomeh Norozi
- Department of Virology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
| |
Collapse
|
5
|
Abdelrahman D, Al-Sadeq DW, Smatti MK, Taleb SA, AbuOdeh RO, Al-Absi ES, Al-Thani AA, Coyle PV, Al-Dewik N, Qahtani AAA, Yassine HM, Nasrallah GK. Prevalence and Phylogenetic Analysis of Parvovirus (B19V) among Blood Donors with Different Nationalities Residing in Qatar. Viruses 2021; 13:v13040540. [PMID: 33805034 PMCID: PMC8063948 DOI: 10.3390/v13040540] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 03/12/2021] [Accepted: 03/14/2021] [Indexed: 12/16/2022] Open
Abstract
Human parvovirus (B19V) is the causative agent of erythema infectiosum in children and is linked to a wide range of clinical manifestations. Studies related to B19V prevalence in the Middle East and North Africa (MENA) region and other parts of Asia are very scarce. The objectives of this study were to estimate the seroprevalence (anti-B19V IgM and IgG), the viremia rate (B19V DNA), and the circulating genotypes of B19V among blood donors in Qatar. Methods: Donors’ blood samples (n = 5026) from different nationalities, mainly from the MENA region and South East Asia, were collected from 2014–2016. Samples were tested for the B19V DNA using RT-PCR. Furthermore, 1000 selected samples were tested to determine the seroprevalence of B19V antibodies using enzyme-linked immunosorbent assay (ELISA). Genotyping was performed on 65 DNA positive samples by sequencing of nested PCR fragments (NS1-VP1u region, 927 nt). Results: Only 1.4% (70/5026) of the samples had detectible B19V DNA in their blood. B19V DNA prevalence statistically decreased with age (p = 0.03). Anti-B19V IgG was detected in 60.3% (561/930) of the tested samples, while only 2.1% (20/930) were IgM-positive and 1.2% (11/930) were both IgM- and IgG-positive. B19V genotyping showed a predominance of Genotype 1 (100%). Sequence analysis of the NS1-VP1u region revealed 139 mutation sites, some of which were amino acid substitutions. Conclusion: Our results indicated a relatively high seroprevalence of B19V in Qatar. Most importantly, B19 DNA was detected among Qatari and non-Qatari blood donors. Therefore, blood banks in Qatar might need to consider screening for B19V, especially when transfusion is intended for high-risk populations, including immunocompromised patients.
Collapse
Affiliation(s)
| | - Duaa W. Al-Sadeq
- Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; (D.W.A.-S.); (M.K.S.); (E.S.A.-A.); (A.A.A.-T.); (H.M.Y.)
- College of Medicine, Member of QU Health, Qatar University, Doha, Qatar
| | - Maria K. Smatti
- Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; (D.W.A.-S.); (M.K.S.); (E.S.A.-A.); (A.A.A.-T.); (H.M.Y.)
- College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar;
| | - Sara A. Taleb
- College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar;
| | - Raed O AbuOdeh
- Medical Laboratory Sciences Department, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates;
| | - Enas S. Al-Absi
- Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; (D.W.A.-S.); (M.K.S.); (E.S.A.-A.); (A.A.A.-T.); (H.M.Y.)
| | - Asmaa A. Al-Thani
- Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; (D.W.A.-S.); (M.K.S.); (E.S.A.-A.); (A.A.A.-T.); (H.M.Y.)
- Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar
| | - Peter. V. Coyle
- Division of Virology, Department of Pathology and Laboratory Medicine, Hamad Medical Corporation, Doha, Qatar;
| | - Nader Al-Dewik
- Department of Pediatrics, Clinical and Metabolic Genetics, Hamad Medical Corporation, Doha, Qatar;
| | - Ahmed A. Al Qahtani
- Department of Infection and Immunity, Research Center, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia;
- Department of Microbiology and Immunology, Alfaisal University School of Medicine, Riyadh 11533, Saudi Arabia
| | - Hadi M. Yassine
- Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; (D.W.A.-S.); (M.K.S.); (E.S.A.-A.); (A.A.A.-T.); (H.M.Y.)
- Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar
| | - Gheyath K. Nasrallah
- Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar; (D.W.A.-S.); (M.K.S.); (E.S.A.-A.); (A.A.A.-T.); (H.M.Y.)
- Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar
- Correspondence:
| |
Collapse
|
6
|
Jia J, Zhong Y, Zhang H, Yuan D, Ma L, Wang D, Zhang J, Ma Y. Identification of human parvovirus 4 genotypes 1 and 2 in Chinese source plasma pools. J Med Virol 2021; 93:4780-4785. [PMID: 33200412 PMCID: PMC8359957 DOI: 10.1002/jmv.26666] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 10/23/2020] [Accepted: 11/09/2020] [Indexed: 12/16/2022]
Abstract
Human parvovirus B19 (B19V) and human parvovirus 4 (PARV4) are known to infect humans and transmit through contaminated blood and blood products. Globally, three genotypes of B19V, as well as PARV4, have been identified, respectively. The existence of different B19V genotypes in Chinese plasma donors has been investigated, however, the data regarding PARV4 were not available. The main objective of this study is to identify the genotypes of PARV4 circulating in Chinese plasma donors. By using a duplex quantitative polymerase chain reaction assay adapted for all genotypes of B19V and PARV4, 78 source plasma pools for fractionation were screened and quantified. Results showed that positive rates of B19V and PARV4 DNA in plasma pool samples were 25.64% and 14.10%, respectively. PARV4 sequences in two positive samples were next genotyped, and these two sequences belonged to PARV4 genotypes 1 and 2, respectively. In conclusion, the data present demonstrate the existence of PARV4 genotypes 1 and 2 in Chinese plasma donors for the first time and also show the relatively lower prevalence and level of PARV4 DNA in Chinese plasma donors in comparison with that of B19V DNA. At least two PARV4 genotypes, 1 and 2, were currently present in China.
The prevalence and level of PARV4 DNA in Chinese plasma donors were relatively lower in comparison with that of B19V DNA.
The rate of B19V and PARV4 coinfection in Chinese source plasma pools was low.
Collapse
Affiliation(s)
- Junting Jia
- Department of Transfusion Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.,NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Yadi Zhong
- NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China.,Department of Hematology, Second Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Huan Zhang
- NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Dian Yuan
- NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Limin Ma
- NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Deqing Wang
- Department of Transfusion Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Jingang Zhang
- NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Yuyuan Ma
- NMPA Key Laboratory for Quality Control of Blood Products, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| |
Collapse
|
7
|
Adamo MP, Blanco S, Viale F, Rivadera S, Rodríguez-Lombardi G, Pedranti M, Carrizo H, Gallego S. Human parvovirus B19 frequency among blood donors after an epidemic outbreak: relevance of the epidemiological scenario for transfusion medicine. Heliyon 2020; 6:e03869. [PMID: 32395652 PMCID: PMC7210410 DOI: 10.1016/j.heliyon.2020.e03869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Revised: 04/22/2020] [Accepted: 04/23/2020] [Indexed: 10/29/2022] Open
Abstract
A retrospective, cross-sectional study was conducted to determine the frequency of human parvovirus B19 (B19V) infected individuals, viral loads and immunity among blood donors from Argentina, in a post-epidemic outbreak period. B19V DNA and specific IgG were tested in minimum study samples of donors attending a blood bank at Córdoba, Argentina, in 2014. Anti-B19V IgM and viral loads were determined in B19V-positive plasma samples. Seven of 731 samples (0.96%) resulted positive, corresponding to individuals aged 32-53 years, four of them repeat donnors and three first-time donors. Viral loads were <103 IU/mL. None had IgM and 6/7 had IgG, one of them at a high level (in the range of 100-200 IU/ml, and the remaining 5 at low to medium level, 5-50 IU/ml). Thus one case was classified as acute infection (DNA+/IgM-/IgG-) and six as potentially persistent infections (DNA+/IgM-/IgG+). No coinfections with other pathogens of mandatory control in the pre-transfusion screening were detected. Prevalence of IgG was 77.9% (279/358). This study provides the first data of B19V prevalence in blood donors in Argentina, demonstrating high rates of acute and persistent B19V infections and high prevalence of anti-B19V IgG in a post-epidemic period. Further research is needed to elucidate mechanisms/factors for B19V persistence as well as follow-up of recipients in the context of haemo-surveillance programs, contributing to the knowledge of B19V and blood transfusion safety.
Collapse
Affiliation(s)
- María Pilar Adamo
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
- Corresponding author.
| | - Sebastián Blanco
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
- Fundación Banco Central de Sangre de Córdoba, Córdoba, Argentina
| | - Franco Viale
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
| | - Sabrina Rivadera
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
| | - Gonzalo Rodríguez-Lombardi
- Departamento de Biología Molecular, Laboratorio de Hemoderivados, Universidad Nacional de Córdoba, Argentina
| | - Mauro Pedranti
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
| | - Horacio Carrizo
- Fundación Banco Central de Sangre de Córdoba, Córdoba, Argentina
| | - Sandra Gallego
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
- Fundación Banco Central de Sangre de Córdoba, Córdoba, Argentina
| |
Collapse
|
8
|
Li X, Lin Z, Liu J, Tang Y, Yuan X, Li N, Lin Z, Chen Y, Liu A. Overall prevalence of human parvovirus B19 among blood donors in mainland China: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2020; 99:e19832. [PMID: 32332630 PMCID: PMC7220778 DOI: 10.1097/md.0000000000019832] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Human parvovirus B19 (B19V) infection exhibits a broad range of clinical outcomes. Blood transfusion is a common route of B19V transmission. However, information about the overall prevalence of B19V infection and B19V genotypes among blood donors in mainland China is lacking. METHODS This meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search for studies reporting the B19V prevalence among blood donors in mainland China from 2000 to 2018 was performed. The prevalence of B19V was estimated through a meta-analysis of the relevant literature. A comprehensive meta-analysis program was used for data processing and statistical analysis. RESULTS Twenty-one eligible articles were included, involving 48,923 participants assessed for B19V-DNA, 12,948 participants assessed for anti-B19V immunoglobulin M (IgM), and 8244 participants assessed for anti-B19V immunoglobulin G (IgG). The analysis revealed the pooled estimates of the prevalence rates of B19V-DNA, anti-B19V IgM, and anti-B19V IgG among blood donors to be 0.7% (95% confidence interval [CI] 0.2-2.4%), 2.7% (95% CI 1.7-4.3%), and 33.6% (95% CI 28.2-39.4%), respectively. Moreover, phylogenetic analyses indicated that 142 of 169 (84.0%) B19V isolates belonged to Genotype 1. CONCLUSIONS The overall prevalence of B19V among blood donors is not high in mainland China, and most isolates belong to Genotype 1.
Collapse
Affiliation(s)
- Xin Li
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
- Department of Blood Transfusion Medicine, School of Medical Technology and Engineering
| | - Zheng Lin
- Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health
| | - Jiayan Liu
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
| | - Yuanyuan Tang
- Department of Rheumatology, Weifang Yidu Central Hospital, Weifang, Shandong Province
| | - Xiaohong Yuan
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
| | - Nainong Li
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
| | - Zhenxing Lin
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
| | - Yuanzhong Chen
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
| | - Ailin Liu
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital
- Department of Pharmaceutical Analysis, Faculty of Pharmacy, Fujian Medical University, Fuzhou, Fujian Province, China
| |
Collapse
|
9
|
Pichon M, Labois C, Tardy-Guidollet V, Mallet D, Casalegno JS, Billaud G, Lina B, Gaucherand P, Mekki Y. Optimized nested PCR enhances biological diagnosis and phylogenetic analysis of human parvovirus B19 infections. Arch Virol 2019; 164:2775-2781. [PMID: 31401693 DOI: 10.1007/s00705-019-04368-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 07/11/2019] [Indexed: 10/26/2022]
Abstract
Diagnosis and epidemiological analysis of human parvovirus B19 (hB19V) infections are essential for disease management in severely ill patients. This study aimed to evaluate the performance of an optimized NS1-VP1u nested PCR for detection and sequencing of viruses in clinical samples using 224 clinical and five reference samples. PCR sensitivity, specificity, and positive and negative predictive values were perfect (100%). While phylogenetic analysis of a 615 bp-long fragment demonstrated that the viruses in all of the samples belonged to genotype 1, this study confirmed that this optimized PCR could detect all known hB19V with high performance.
Collapse
Affiliation(s)
- Maxime Pichon
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et de Pathologie Nord, 103, grande rue de la Croix-Rousse, 69 317, Lyon cedex 04, France. .,Université Lyon 1 Claude Bernard, CIRI, Virpath, Inserm U1111-CNRS UMR 5308, ENS, Lyon, France.
| | - Clément Labois
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et de Pathologie Nord, 103, grande rue de la Croix-Rousse, 69 317, Lyon cedex 04, France
| | - Véronique Tardy-Guidollet
- Hospices Civils de Lyon, Laboratoire d'Endocrinologie Moléculaire, Centre de Biologie et de Pathologie Est, Bron, France
| | - Delphine Mallet
- Hospices Civils de Lyon, Laboratoire d'Endocrinologie Moléculaire, Centre de Biologie et de Pathologie Est, Bron, France
| | - Jean-Sébastien Casalegno
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et de Pathologie Nord, 103, grande rue de la Croix-Rousse, 69 317, Lyon cedex 04, France.,Université Lyon 1 Claude Bernard, CIRI, Virpath, Inserm U1111-CNRS UMR 5308, ENS, Lyon, France
| | - Geneviève Billaud
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et de Pathologie Nord, 103, grande rue de la Croix-Rousse, 69 317, Lyon cedex 04, France
| | - Bruno Lina
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et de Pathologie Nord, 103, grande rue de la Croix-Rousse, 69 317, Lyon cedex 04, France.,Université Lyon 1 Claude Bernard, CIRI, Virpath, Inserm U1111-CNRS UMR 5308, ENS, Lyon, France
| | - Pascal Gaucherand
- Hospices civils de Lyon, Service de Gynécologie-Obstétrique, Hôpital Femme-Mère-Enfant, Bron, France
| | - Yahia Mekki
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et de Pathologie Nord, 103, grande rue de la Croix-Rousse, 69 317, Lyon cedex 04, France
| |
Collapse
|
10
|
Salbetti MB, Pedranti MS, Barbero P, Molisani P, Lazzari M, Olivera N, Isa MB, Bertoldi A, Moreno L, Adamo MP. Molecular screening of the human parvoviruses B19 and bocavirus 1 in the study of congenital diseases as applied to symptomatic pregnant women and children. Access Microbiol 2019; 1:e000037. [PMID: 32974527 PMCID: PMC7470285 DOI: 10.1099/acmi.0.000037] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 06/12/2019] [Indexed: 12/22/2022] Open
Abstract
Introduction B19 virus (B19V) and bocavirus 1 (HBoV1) are human pathogenic parvoviruses that are prevalent worldwide and are responsible for a diverse and not yet fully established spectrum of clinical manifestations. Objective To screen B19V and HBoV1 in patients with clinical manifestations associated with acquisition of the infection during gestation. Methods A retrospective, observational study was performed that included serum samples from patients without a previous known aetiology. B19V and HBoV1 were determined by end-point PCR. Positive samples were genotyped. Results A total of 106 serum samples were analysed, 61 from pregnant women and 45 from neonates and paediatric patients. None were positive for HBoV1, while B19V was detected in 37/106 [34.9 %, 95 % confidence interval (CI): 26.5–44.4] of the samples studied. In the group of pregnant women, 28/61 (45.9 %, 95 % CI: 34.0–58.3) were B19V-positive, and 2 of them had foetal anaemia followed by hydrops and foetal death, 3 were associated with a history of recurrent pregnancy loss and there was 1 case of spontaneous abortion. B19V was also detected in cases of maternal febrile exanthema, polyhydramnios, oligohydramnios and foetal ascites. In the group of children, 9/45 (20.0 %, 95 % CI: 10.9–33.8) neonatal patients were B19V-positive, and this was associated with foetal hydrops, TORCH syndrome and cardiac alterations. The nucleotide sequences analysed confirmed the identity of B19V genotype 1. Conclusions We found no evidence to indicate the presence of HBoV1 in maternal blood or in the newborns/paediatric patients (hence providing no support for the supposed vertical transmission). On the other hand, the high frequency of B19V in the pathologies studied indicates the importance of molecular diagnosis in both the mother and the child. Future efforts should contribute to early detection and characterization of infections.
Collapse
Affiliation(s)
- Maria Belen Salbetti
- Laboratorio de Rubéola y Parvovirus, Instituto de Virología “Dr J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enf. Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | - Mauro Sebastian Pedranti
- Laboratorio de Rubéola y Parvovirus, Instituto de Virología “Dr J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enf. Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | - Paula Barbero
- Área de Epidemiología, Ministerio de Salud de la Provincia de Córdoba, Av. Vélez Sarsfield 2311, Córdoba, Argentina
| | - Paula Molisani
- Laboratorio de Rubéola y Parvovirus, Instituto de Virología “Dr J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enf. Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | - Martina Lazzari
- Laboratorio de Rubéola y Parvovirus, Instituto de Virología “Dr J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enf. Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | - Nicolas Olivera
- Laboratorio de Rubéola y Parvovirus, Instituto de Virología “Dr J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enf. Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | - Maria Beatriz Isa
- Clínica Universitaria Reina Fabiola, Córdoba, Oncativo 1248, Córdoba, Argentina
| | - Ariel Bertoldi
- Clínica Universitaria Reina Fabiola, Córdoba, Oncativo 1248, Córdoba, Argentina
| | - Laura Moreno
- Cátedra de Clínica Pediátrica, Hospital Universitario de Maternidad y Neonatología, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Rodríguez Peña 285, Córdoba, Argentina
| | - Maria Pilar Adamo
- Laboratorio de Rubéola y Parvovirus, Instituto de Virología “Dr J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enf. Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
- *Correspondence: Maria Pilar Adamo,
| |
Collapse
|
11
|
Eid AJ, Ardura MI. Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13535. [PMID: 30973192 DOI: 10.1111/ctr.13535] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 02/27/2019] [Indexed: 12/21/2022]
Abstract
Clinical manifestations of human parvovirus B19 infection can vary widely and may be atypical in solid organ transplant (SOT) recipients. However, disease is apparent when there is destruction of erythrocyte progenitor cells leading to severe acute or chronic anemia with lack of an appropriate reticulocyte response in the setting of active parvovirus B19 infection. Serology may not reliably establish the diagnosis. High-level viremia is more likely to be associated with symptomatic disease. Conversely, ongoing DNAemia after infection may not be clinically significant, if detected at low levels. Despite lack of robust data, intravenous immunoglobulin (IVIG) is frequently used for the treatment of SOT recipients with symptomatic parvovirus B19 infection. Although the optimal dosage and duration of IVIG is not known, most patients receive a total of 2 g/kg over a period of 2-5 days. A daily dose of 1 g/kg or more seems to be associated with higher incidence of toxicity. Application of standard and droplet isolation precautions remains the cornerstone for preventing human parvovirus B19 transmission. Additional research is needed to assess the efficacy of current and novel therapies and to develop a safe and effective parvovirus B19 vaccine.
Collapse
Affiliation(s)
- Albert J Eid
- Department of Internal Medicine, Infectious Diseases, The University of Kansas Medical Center, Kansas City, Kansas
| | - Monica I Ardura
- Department of Pediatrics, Infectious Diseases and Host Defense, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio
| | | |
Collapse
|
12
|
Francois KL, Parboosing R, Moodley P. Parvovirus B19 in South African blood donors. J Med Virol 2019; 91:1217-1223. [PMID: 30840773 DOI: 10.1002/jmv.25450] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 02/01/2019] [Accepted: 02/25/2019] [Indexed: 02/04/2023]
Abstract
BACKGROUND Parvovirus B19 (PVB19) is transmitted via transfusion of blood and blood products. PVB19 is resistant to viral inactivation methods, which poses a threat to blood safety. We investigated the prevalence of PVB19 antibodies and DNA in healthy blood donors from the South African National Blood Bank Service to evaluate the necessity of PVB19 DNA testing. STUDY DESIGN AND METHOD A retrospective analysis of 1500 residual plasma specimens from healthy blood donors from the SANBS repository were screened in mini-pools of 20 for PVB19 DNA using a quantitative polymerase chain reaction (PCR). Positive pools were resolved by individual viral load testing and screened for PVB19 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies to correlate viral loads with serological status. PVB19 IgG prevalence was determined by testing 90 randomly selected specimens from the 1500 plasma specimens. RESULTS The prevalence of PVB19 IgG, IgM and IgG, and DNA was 62.2%, 0.06%, and 0.9%, respectively. Fourteen of the 1500 blood donor specimens received, had detectable PVB19 viral loads. Nine of the fourteen donors with detectable viral loads were PVB19 IgG seropositive. The PVB19 viral loads ranged from 1.81 to 5.32 log IU/mL. Four of the fourteen viraemic donors had a viraemia >10 4 IU/mL. CONCLUSION We have demonstrated a low prevalence of PVB19 DNA in SANBS blood donors. The predominance of low-level viraemia and the presence of PVB19 antibodies, suggests that the risk of transfusion transmission of PVB19 among SANBS donors may be relatively low.
Collapse
Affiliation(s)
- Kerri Lee Francois
- Department of Virology, National Health Laboratory Service and University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
| | - Raveen Parboosing
- Department of Virology, National Health Laboratory Service and University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
| | - Pravi Moodley
- Department of Virology, National Health Laboratory Service and University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
| |
Collapse
|
13
|
Aydin H, Timurkan MO, Aktas O. Genetic diversity of primate erythroparvovirus 1 between 2009 and 2016: First report from Turkey. Microb Pathog 2019; 129:131-135. [PMID: 30742946 DOI: 10.1016/j.micpath.2019.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 02/06/2019] [Accepted: 02/07/2019] [Indexed: 10/27/2022]
Abstract
Parvovirus B19 (B19V) is one of the major viral pathogens that infect only human beings. This study's aim is to determine which genotypes of the B19V are present in Turkey and to perform a phylogenetic analysis. Twelve B19V positive serum specimens already diagnosed by real-time PCR amplifying a partial region of the NS gene were included in this study. The serological markers and viral loads of the patients were determined. The positivity of the specimens was confirmed using semi-nested PCR. To determine the genotype of the B19V, PCR-positive amplicons were sequenced directly and compared to GenBank-referenced strain sequences. The phylogeny of the 12 sequenced strains was constructed with the maximum likelihood method. Two different genotypes of B19V were identified in our study. Genotype 2 of B19V was not detected. All of the B19V genotype 1 sequences were clustered in the common genotype 1a cluster (10/12, 83.3%). The average quantification of the B19V strains was determined to be 2.1 × 107 IU/ml. The nucleotide identities between our strains and those isolated in other countries were 85.8%-99.5%. Compared to the Turkish strains identified in our study, at the nucleotide level, the closest strains based on genotypes 3b and 1a were the Germany and Netherlands isolates respectively. This study was the first to provide the genotypic variation of B19V circulated in Turkey. We determined two distinct subtypes of B19V, including subtype 3b and 1a. While the genotype 1 is common all over the world, genotype 3 has begun to spread outside of Africa.
Collapse
Affiliation(s)
- Hakan Aydin
- Ataturk University, Faculty of Veterinary Medicine, Department of Virology, 25240, Erzurum, Turkey.
| | - Mehmet Ozkan Timurkan
- Ataturk University, Faculty of Veterinary Medicine, Department of Virology, 25240, Erzurum, Turkey
| | - Osman Aktas
- Ataturk University, Faculty of Medicine, Department of Microbiology, 25240, Erzurum, Turkey
| |
Collapse
|
14
|
Jia J, Zhong Y, Guo Y, Huangfu C, Zhao X, Fang C, Fan R, Ma Y, Zhang J. Simultaneous detection and differentiation of human parvovirus B19 and human parvovirus 4 by an internally controlled multiplex quantitative real-time PCR. Mol Cell Probes 2017; 36:50-57. [PMID: 28863892 DOI: 10.1016/j.mcp.2017.08.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 08/28/2017] [Accepted: 08/28/2017] [Indexed: 02/03/2023]
Abstract
Human parvovirus B19 (B19V) and human parvovirus 4 (PARV4) are two parvoviruses known to infect humans and transmit through blood and plasma derived medicinal products (PDMPs). Inactivation of the two parvoviruses has proven to be difficult and nucleic acid testing (NAT) would be an efficient means to exclude viruses. In this study, an internally controlled multiplex quantitative real-time PCR (qPCR) assay for B19V and PARV4 simultaneous detection and quantification was established and evaluated. The optimized multiplex qPCR assay allowed for simultaneous detection of all of the genotypes (1-3) of B19V and PARV4, with equal limit of quantification (LOQ) of 5 copies/μL, rather than other blood-borne viruses. It had a wide dynamic range of reliable amplification linearity of at least 8 orders of magnitude. Low standard deviations (SD) of quantification cycle (Cq) values and low coefficients of variation (CV) of copy numbers for both B19V and PARV4 suggested a high level of repeatability and reproducibility for the multiplex qPCR assay. This multiplex qPCR assay can be served as a readily applicable approach to screen plasma units intended for further manufacturing into PDMPs to reduce the risk of parvoviruses infection by such products and may also be useful for the detection of B19V/PARV4 co-infection or co-existence.
Collapse
Affiliation(s)
- Junting Jia
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Yadi Zhong
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Yi Guo
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China; Shaanxi Blood Center, Xi'an 710000, China.
| | - Chaoji Huangfu
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Xiong Zhao
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Chi Fang
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Rui Fan
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Yuyuan Ma
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| | - Jingang Zhang
- Beijing Key Laboratory of Blood Safety and Supply Technologies & Blood Products and Substitute Laboratory, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
| |
Collapse
|